#USA #San Francisco #Telix Pharmaceuticals #FDA CRL #SEC Subpoena

Hagens Berman Issues Urgent Warning to Telix Investors

In a crucial update for investors of Telix Pharmaceuticals Ltd. (NASDAQ: TLX), the national shareholder rights law firm Hagens Berman has stressed that the deadline to apply for lead plaintiff status in a class action lawsuit against the company is set for January 9, 2026. This comes in light of alleged regulatory failures that have culminated in significant stock price drops and investor losses.

Unraveling the Allegations

The lawsuit is rooted in allegations against Telix and its executives for overstating the developmental progress of critical therapeutic candidates TLX591 and TLX592, while simultaneously misrepresenting their third-party manufacturing partners' reliability and adherence to regulations.

Reed Kathrein, a partner at Hagens Berman who is leading the litigation, has pointed out discrepancies between management's optimistic claims and the troubling regulatory scrutiny the company has faced. The timely filing is critical for stakeholders who may have incurred considerable losses following the negative revelations about the company’s operational failures.

Two Key Regulatory Concerns

Hagens Berman's case highlights two significant regulatory events impacting Telix and its investors:

1. SEC Investigation: On July 22, 2025, the company disclosed an SEC subpoena related to its prostate cancer therapeutics. This development raised concerns over potential misleading statements made regarding the progression of drug development and investor information on the current status of these projects.

2. FDA Complete Response Letter (CRL): The FDA's rejection of Telix's Zircaix (TLX250-CDx) application on August 28, 2025, citing failures in Chemistry, Manufacturing, and Controls, has raised alarms about the integrity of the company’s third-party supply chain. This disclosure marked a pivotal moment as it revealed documented deficiencies at the company’s manufacturing partners, notably captured in two Form 483 notices issued to them.

The adverse stock reaction following these announcements, including a 21% decline, underscores the gravity of the situation and its implications for investors.

Call to Action for Investors

Hagens Berman is actively encouraging affected Telix investors—particularly those who bought shares during the Class Period from February 21, 2025, to August 28, 2025—to come forward. The firm specializes in recovering losses for those impacted by corporate misrepresentations and malpractices.

If you have been impacted by these developments and wish to discuss your rights and options, Hagens Berman is poised to guide you through the legal landscape surrounding this class action. The firm has emphasized the importance of filing by January 9, 2026, to secure your potential claims.

To formally submit your losses or to gather more information, interested parties can reach out to Reed Kathrein at 844-916-0895 or email [email protected]

Hagens Berman’s Commitment

Hagens Berman is well-known for its advocacy in securing justice for investors and has achieved significant recoveries exceeding $2.9 billion in various cases. The firm represents not just investors, but also whistleblowers, consumers, and other parties that have faced corporate negligence and misconduct.

As this situation continues to unfold, stakeholders in Telix Pharmaceuticals must stay alert and proactive. For ongoing updates and news, consider following Hagens Berman’s official updates @ClassActionLaw.

In summary, the upcoming January deadline serves as a pivotal moment for Telix investors to act decisively amidst a backdrop of regulatory scrutiny and alleged misrepresentations that have impacted the company's operational integrity.